Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Grand View Research | PRODUCT CODE: 1654203

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1654203

Breast Cancer Core Needle Biopsy Market Size, Share & Trends Analysis Report By Technology, By End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Breast Cancer Core Needle Biopsy Market Growth & Trends:

The global breast cancer core needle biopsy market size is estimated to reach USD 1.15 billion by 2030, registering to grow at a CAGR of 4.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. The market growth is primarily propelled by factors such as the increasing prevalence of breast cancer, the widespread recommendations for regular mammography screenings, rising awareness among individuals, and extensive research studies conducted in this field. These factors collectively contribute to the rising demand and adoption of breast cancer core needle biopsy procedures, paving the way for significant growth in the coming years.

Additionally, continuous advancements in imaging technologies and biopsy techniques contribute to the expansion of the industry. There is a growing recognition of the crucial role that early detection and diagnosis play in improving patient outcomes. Core needle biopsies offer distinct advantages over traditional open surgical biopsies, including reduced invasiveness, quicker recovery time, and cost-effectiveness.

As the demand for early detection and diagnosis continues to rise, the market for breast cancer core needle biopsy is expected to witness significant growth. A recent example of innovative research in this field involves the use of contrast-mammography-guided breast biopsies that utilize MRI technology for lesion visualization, as demonstrated by researchers at the IMIM (Hospital del Mar Medical Research Institute) in Spain, in 2022 with the findings published in the journal European Radiology.

The COVID-19 pandemic has both challenged and opened new opportunities in the breast cancer core needle biopsy market. Delays in non-essential procedures have led to a decrease in diagnosis rate and demand for core needle biopsies. However, the pandemic has emphasized the importance of early detection, leading healthcare providers to prioritize screenings and biopsies, resulting in a resurgence in demand.

Breast Cancer Core Needle Biopsy Market Report Highlights:

  • The ultrasound-based breast biopsy segment accounted for the largest revenue share of 41.9% in 2024. The segment dominance can be attributed to the growing preference for ultrasound-guided biopsies due to their notable advantages.
  • The hospitals & diagnostic laboratories segment captured the highest revenue share of 60.0% in 2024.
  • The academic & research institutes segment is predicted to grow at an exponential CAGR of 4.4% from 2025 to 2030 in the breast cancer core needle biopsy industry.
  • North America breast cancer core needle biopsy industry dominated and accounted for a 46.26%of revenue share in 2024.
Show more
Product Code: GVR-4-68040-161-0

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. End use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Breast Cancer Core Needle Biopsy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing prevalence of breast cancer
      • 3.2.1.2. Advancement in imaging technologies and biopsy techniques
      • 3.2.1.3. Rising inclination towards minimally invasive procedures
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of core needle biopsy procedures
      • 3.2.2.2. Limited expertise and training
  • 3.3. Breast Cancer Core Needle Biopsy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Breast Cancer Core Needle Biopsy Market: Technology Estimates & Trend Analysis

  • 4.1. Technology Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Breast Cancer Core Needle Biopsy Market by Technology Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. MRI-Based Breast Biopsy
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.2. Fermentation Ultrasound-Based Breast Biopsy
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Mammography-Based (Stereotactic) Breast Biopsy
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. CT-Based Breast Biopsy
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Other Image-Based Breast Biopsy
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Breast Cancer Core Needle Biopsy Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Breast Cancer Core Needle Biopsy Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hospitals & Diagnostic Laboratories
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 5.4.2. Pharmaceutical & Biotechnology companies
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Academic & Research Institutes
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Breast Cancer Core Needle Biopsy Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Target Disease Prevalence
      • 6.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Target Disease Prevalence
      • 6.5.2.4. Competitive scenario
      • 6.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Target Disease Prevalence
      • 6.5.3.4. Competitive scenario
      • 6.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Target Disease Prevalence
      • 6.6.1.4. Competitive scenario
      • 6.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Target Disease Prevalence
      • 6.6.2.4. Competitive scenario
      • 6.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Target Disease Prevalence
      • 6.6.3.4. Competitive scenario
      • 6.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Target Disease Prevalence
      • 6.6.4.4. Competitive scenario
      • 6.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Target Disease Prevalence
      • 6.6.5.4. Competitive scenario
      • 6.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Target Disease Prevalence
      • 6.6.6.4. Competitive scenario
      • 6.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Target Disease Prevalence
      • 6.6.7.4. Competitive scenario
      • 6.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Target Disease Prevalence
      • 6.6.8.4. Competitive scenario
      • 6.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Target Disease Prevalence
      • 6.7.1.4. Competitive scenario
      • 6.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Target Disease Prevalence
      • 6.7.2.4. Competitive scenario
      • 6.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Target Disease Prevalence
      • 6.7.3.4. Competitive scenario
      • 6.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Target Disease Prevalence
      • 6.7.4.4. Competitive scenario
      • 6.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Target Disease Prevalence
      • 6.7.5.4. Competitive scenario
      • 6.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Target Disease Prevalence
      • 6.7.6.4. Competitive scenario
      • 6.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Target Disease Prevalence
      • 6.8.1.4. Competitive scenario
      • 6.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Target Disease Prevalence
      • 6.8.2.4. Competitive scenario
      • 6.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Target Disease Prevalence
      • 6.9.1.4. Competitive scenario
      • 6.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Target Disease Prevalence
      • 6.9.2.4. Competitive scenario
      • 6.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Target Disease Prevalence
      • 6.9.3.4. Competitive scenario
      • 6.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Target Disease Prevalence
      • 6.9.4.4. Competitive scenario
      • 6.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company market share analysis, 2024
    • 7.3.2. Intact Medical Corporation
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Ethicon Surgical Technologies
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Gallini SRL
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Leica Biosystems Nussloch GmbH
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Hologic, Inc
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Argon Medical Devices
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Encapsule Medical Devices LLC
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Cook Medical Incorporated
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Becton, Dickinson and Company
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. C.R. Bard, Inc.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-161-0

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 3 Global breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 4 Global breast cancer core needle biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 5 North America breast cancer core needle biopsy market, by country, 2018 - 2030 (USD Million)
  • Table 6 North America breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 7 North America breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 U.S. breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 9 U.S. breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 10 Canada breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 11 Canada breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Mexico breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 13 Mexico breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Europe breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 15 Europe breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 16 Europe breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 17 UK breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 18 UK breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 19 Germany breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 20 Germany breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 21 France breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 22 France breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 23 Italy breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 24 Italy breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Spain breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 26 Spain breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 27 Denmark breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 28 Denmark breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Sweden breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 30 Sweden breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Norway breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 32 Norway breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 36 Japan breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 37 Japan breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 38 China breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 39 China breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 40 India breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 41 India breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 42 Australia breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 43 Australia breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 44 Thailand breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 45 Thailand breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 46 South Korea breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 47 South Korea breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 48 Latin America breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 49 Latin America breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 50 Latin America breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 51 Brazil breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 52 Brazil breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Argentina breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 54 Argentina breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa breast cancer core needle biopsy, by technology, 2018-2030, (USD
  • Table 57 Middle East & Africa breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 58 South Africa breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 59 South Africa breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 62 UAE breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 63 UAE breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 64 Kuwait breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 65 Kuwait breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 breast cancer core needle biopsy market segmentation
  • Fig. 8 Market snapshot, 2024
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's Five Forces analysis
  • Fig. 14 Global breast cancer core needle biopsy market: Technology movement analysis
  • Fig. 15 Global breast cancer core needle biopsy market, for MRI-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 16 Global breast cancer core needle biopsy market, for ultrasound-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 17 Global breast cancer core needle biopsy market, for mammography-based (stereotactic) breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 18 Global breast cancer core needle biopsy market, for CT-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 19 Global breast cancer core needle biopsy market, for other image-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 20 Global breast cancer core needle biopsy market: End use movement analysis
  • Fig. 21 Global breast cancer core needle biopsy market, for hospitals & diagnostic laboratories, 2018 - 2030 (USD Million)
  • Fig. 22 Global breast cancer core needle biopsy market, for pharmaceutical & biotechnology companies, 2018 - 2030 (USD Million)
  • Fig. 23 Global breast cancer core needle biopsy market, for academic & research institutes, 2018 - 2030 (USD Million)
  • Fig. 24 Regional marketplace: Key takeaways
  • Fig. 25 Regional outlook, 2024 & 2030
  • Fig. 26 Global breast cancer core needle biopsy market: Region movement analysis
  • Fig. 27 North America breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 29 Canada breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 30 Mexico breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 32 Germany breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 33 UK breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 34 France breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 35 Italy breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 36 Spain breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 41 Japan breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 42 China breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 43 India breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 44 Australia breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 45 South Korea breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 46 Thailand breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 49 Argentina breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 50 Middle East and Africa breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 51 South Africa breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 52 Saudi Arabia breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 53 UAE breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 54 Kuwait breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!